For its fourth fiscal quarter (ending December 31), EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) has reported a 94% increase in E.P.S. from $-0.33 a year ago to $-0.64 in the current quarter. E.P.S. were $-2.32 for the latest four quarters through December 31 versus $-1.82 for the same period a year ago — an increase of 27%.
Recent Price Action
On 3/5/25, EyePoint Pharmaceuticals Inc (NASDAQ: EYPT) stock enjoyed a very large increase of 8.2%, closing at $6.58. This advance was accompanied by normal trading volume. Relative to the market the stock has been weak over the last nine months but has risen 10.4% during the last week.
Current PriceTarget Research Rating
EyePoint Pharmaceuticals has a current Value Trend Rating of C (Neutral). This rating combines contradictory signals from two proprietary PTR measures of a stock’s attractiveness. EyePoint Pharmaceuticals has a slightly positive Appreciation Score of 69 but a slightly negative Power Rating of 31, resulting in the Neutral Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment